Evidence map›Paper›PMID 26261488›Full record

ArticleInternational journal of clinical and experimental pathology2015

Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells.

Ren Feng, Lei Dong

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. MiRNAs: main players of cancer drug resistance target ABC transporters.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Hippo Pathway in Regulating Drug Resistance of Glioblastoma.International journal of molecular sciences · 2021
    Review
  7. Emerging targets in cancer drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2019
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Ren FengDepartment of Medical Administration, Tianjin Huanhu Hospital Tianjin 300060, China.
Lei DongDepartment of Pediatrics, Division of Hematology/Oncology, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine Atlanta, GA 30322, USA.
Emory University · USTianjin Huanhu Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate signaling pathways for reversal of microRNA-127-mediated multi-drug resistance (MDR) in gliomas cells. Adriamycin-resistant glioma cell lines U251/adr and U87-MG/adr were established and we found that anti-microRNA-127 markedly reduced microRNA-127 expression levels in a time-dependent manner, leading to distinct inhibition of cell proliferation and increased apoptosis and the content of intracellular Rh123. Silencing of microRNA-127 significantly increased the sensitivity of U251/ADR and U87-MG/adr cells to adriamycin, compared to cells transfected with negative control siRNA. Silencing of microRNA-127 also significantly reduced the mRNA and protein expression levels of MDR1 and MRP1, which are major ATP-binding cassette (ABC) transporter linked to multi-drug resistance in cancer cells. And Runx2, p53, bcl-2 and survivin, which are important role in cell apoptosis, also markedly changed after microRNA-127 silencing. In addition, down-regulating microRNA-127 decreased the level of phosphorylated-Akt. Our data indicate that down-regulation of micorRNA-127 can trigger apoptosis and overcome drug resistance of gliomas cells. Therefore, this resistance of adriamycin in gliomas can be cancelled by silencing expression of microRNA-127.

Indexed as

Gene Knockdown TechniquesRNA InterferenceAntibiotics, AntineoplasticApoptosisATP-Binding Cassette, Sub-Family C ProteinsATP Binding Cassette Transporter, Subfamily BBrain NeoplasmsCell Cycle CheckpointsCell Line, TumorCell ProliferationCore Binding Factor Alpha 1 SubunitDose-Response Relationship, DrugDown-RegulationDoxorubicinDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticABCB1 protein, humanAntibiotics, AntineoplasticATP-Binding Cassette, Sub-Family C ProteinsATP Binding Cassette Transporter, Subfamily BBCL2 protein, humanBIRC5 protein, humanCore Binding Factor Alpha 1 SubunitDoxorubicinInhibitor of Apoptosis ProteinsMicroRNAsMIRN127 microRNA, humanmultidrug resistance-associated protein 1Proto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2RUNX2 protein, humanSurvivinTP53 protein, humanTumor Suppressor Protein p53adriamycindrug resistance reversalgliomasmicroRNA-127

Identifiers

PMID26261488
PMCPMC4525822
OpenAlexW1151087721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.